Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

PTERIDINES is a unique journal dedicated to the study of pteridines and their implications in biochemistry and clinical research. Published by DE GRUYTER POLAND SP Z O O, this Open Access journal has been a vital resource since its inception in 1989, steadily evolving to include a diverse range of topics pertinent to molecular medicine and biochemistry. With its current classification in the Q4 quartile for Biochemistry, Clinical Biochemistry, and Molecular Medicine, PTERIDINES offers a platform for researchers and professionals seeking to disseminate and access groundbreaking findings. Although the journal has a modest Scopus ranking, it serves as an important outlet for both emerging and established scholars in the field, particularly those focusing on the biochemical roles of pteridines. Based in Germany, the journal invites contributions from around the globe, providing equitable access to all readers since 2018, making significant strides towards inclusive scientific discourse. As such, PTERIDINES is a valuable asset for anyone engaged in the exploration of pteridines and their multifaceted roles in health and disease.

PLASMA PHYSICS REPORTS, published by PLEIADES PUBLISHING INC, is a distinguished journal that caters to the intricate and evolving field of plasma physics and its applications within condensed matter physics and astronomy. With an ISSN of 1063-780X and an E-ISSN of 1562-6938, the journal serves as a pivotal platform for researchers, professionals, and students to disseminate groundbreaking work and foster collaboration among experts in the field. The journal operates as a non-open access resource, contributing to its reputation for curating high-quality research findings. Over its converged years from 1996 to 2024, the journal has established itself within the Q3 category across both condensed matter physics and miscellaneous physics and astronomy in the 2023 quartiles. With current Scopus rankings placing it in the 42nd percentile for physics and astronomy and the 27th percentile for condensed matter physics, PLASMA PHYSICS REPORTS stands as a vital resource for advancing knowledge and innovation in plasma research.

Transfusionsmedizin is a premier journal dedicated to the field of transfusion medicine, published by the renowned GEORG THIEME VERLAG KG. With an ISSN of 2191-8805 and an E-ISSN of 2191-8813, this journal serves as a vital platform for disseminating cutting-edge research and clinical advancements in blood transfusion practices. Although it operates under a subscription model, the journal is committed to high-quality peer-reviewed content that addresses contemporary challenges and innovations in transfusion therapy. By fostering dialogue among researchers, clinicians, and students, Transfusionsmedizin aims to advance patient care and enhance the safety and efficacy of transfusion practices globally. Its contributions are essential for professionals engaged in transfusion science, hematology, and related medical fields, solidifying its reputation as a critical resource for staying abreast of the latest developments in transfusion research.

HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.

Lancet Haematology, published by Elsevier Science Ltd in the United Kingdom, is a premier peer-reviewed journal dedicated to advancing the field of hematology. With an impressive impact factor and listed in the Q1 category in hematology for 2023, this journal ranks #4 out of 137 in the Scopus database, boasting a 97th percentile indicating its influential role in disseminating high-quality research. Since its establishment in 2014, Lancet Haematology has provided a vital platform for researchers and clinicians to share groundbreaking studies, innovative treatment approaches, and novel therapeutic discoveries relevant to various hematological disorders. The journal does not operate under an open access model, but it offers multiple access options to facilitate engagement with its content. By bridging clinical practice and cutting-edge research, Lancet Haematology aims to foster the advancement of knowledge and improve patient outcomes in hematology, making it an essential read for professionals, researchers, and students alike.

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

Mediterranean Journal of Hematology and Infectious Diseases is a distinguished open access journal published by MATTIOLI 1885, dedicated to advancing the field of hematology and infectious diseases. Since its inception in 2009, the journal has provided a platform for researchers and practitioners to disseminate innovative findings, foster scholarly discourse, and enhance our understanding of these critical medical disciplines. With an impact factor reflecting its scholarly influence, it is recognized in the Q3 quartile for both Hematology and Infectious Diseases categories as of 2023. The journal's commitment to open access ensures that high-quality research is accessible to a global audience, contributing to the improvement of clinical practices and public health. Located in Fidenza, Italy, the journal continues to support converged research efforts from 2010 to 2024, making it an essential resource for academics, clinicians, and students in the medical community.

Experimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.

Plasma is a leading open-access journal published by MDPI, devoted to the exploration and advancement of knowledge in the fields of engineering, physics, and materials science. Established in 2018, this journal provides a vital platform for researchers, professionals, and students to disseminate original findings and critical reviews related to plasma science, its applications, and its interdisciplinary aspects. With an E-ISSN of 2571-6182, Plasma actively promotes open access to ensure that research is widely accessible, reinforcing its commitment to accelerating scientific communication and collaboration across global communities. The journal enjoys respectable rankings in Scopus, with a notable position in Engineering, Physics and Astronomy, and Materials Science categories, making it an essential resource for those seeking to remain at the forefront of plasma research. Covering a range of topics until 2024, Plasma invites cutting-edge contributions that push the boundaries of understanding in this dynamic field.